IL10-TCE

IL10-TCE is an experimental, next-generation T-cell engager (TCE) designed to treat solid tumors by addressing T-cell dysfunction in the tumor microenvironment. It consists of an IL-10 cytokine fused to the N-terminus of an anti-CD3 arm via a cleavable linker, a configuration referred to as a "pro-TCE." This design aims to deliver IL-10 specifically to the tumor site, where IL-10 receptors are enriched on antigen-specific T cells. By providing localized IL-10 signaling, the drug counteracts activation-induced cell death (AICD) and T-cell exhaustion, which are common limitations of traditional TCE therapies. Preclinical studies presented at the AACR 2026 Annual Meeting demonstrated that IL10-TCE promotes the expansion of tumor-infiltrating lymphocytes and leads to the complete regression of established solid tumors and metastatic lesions in models of colon cancer, melanoma, and pancreatic cancer, without systemic toxicity.

Other names

cleavable IL10-TCEIL-10-integrated T cell engagerIL10-integrated T cell engagerIL 10-integrated T cell engagerpro-TCE